Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
Anais Brasileiros de Dermatologia · 2025
DOI: 10.1016/j.abd.2024.08.002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Anais Brasileiros de Dermatologia, 2025. Verfasst von Tania F Cestari und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic addr…. Hauptthemen laut MEDLINE: Psoriasis, Methotrexate, Dermatologic Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: tcestari@hcpa.edu.br.
- Division of Dermatology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
- Instituto de Dermatologia e Estética do Rio de Janeiro, Rio de Janeiro, Brazil.
- Department of Dermatology, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brazil.
- Department of Dermatology, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.
- Discipline of Dermatology, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.
Förderung
- AbbVie
Zitieren
APA
Cestari, T. F., Souza, C. D. S., Azulay-Abulafia, L., Romiti, R., Carvalho, A. V. E., Silva de Castro, C. C., Marques, S. A., Antonio, J. R., Fabrício, L., Soliman, A. M., Wu, T., Sinvhal, R., Stakias, V., Song, A. P., Kalabic, J., Martin, N., & Oyafuso, L. K. M. (2025). Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2024.08.002
Vancouver
Cestari TF, Souza CDS, Azulay-Abulafia L, Romiti R, Carvalho AVE, Silva de Castro CC, et al. Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. Anais Brasileiros de Dermatologia. 2025. doi:10.1016/j.abd.2024.08.002
BibTeX
@article{Cestari2025,
author = {Cestari, Tania F and Souza, Cacilda da Silva and Azulay-Abulafia, Luna and Romiti, Ricardo and Carvalho, André V E and Silva de Castro, Caio César and Marques, Sílvio Alencar and Antonio, João Roberto and Fabrício, Lincoln and Soliman, Ahmed M and Wu, Tianshuang and Sinvhal, Ranjeeta and Stakias, Vassilis and Song, Alexandra P and Kalabic, Jasmina and Martin, Naomi and Oyafuso, Luiza Keiko Matsuka},
title = {Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil},
journal = {Anais Brasileiros de Dermatologia},
year = {2025},
doi = {10.1016/j.abd.2024.08.002}
}
EUVIMED